These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37484098)

  • 21. Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer's disease.
    Siafarikas N; Selbaek G; Fladby T; Šaltytė Benth J; Auning E; Aarsland D
    Int Psychogeriatr; 2018 Jan; 30(1):103-113. PubMed ID: 28927477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visual Event-Related Potentials in Mild Cognitive Impairment and Alzheimer's Disease: A Literature Review.
    Morrison C; Rabipour S; Taler V; Sheppard C; Knoefel F
    Curr Alzheimer Res; 2019; 16(1):67-89. PubMed ID: 30345915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olfactory function changes and the predictive performance of the Chinese Smell Identification Test in patients with mild cognitive impairment and Alzheimer's disease.
    Mi Y; Ma X; Du S; Du C; Li X; Tan H; Zhang J; Zhang Q; Shi W; Zhang G; Tian Y
    Front Aging Neurosci; 2023; 15():1068708. PubMed ID: 36861124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer's disease in patients with mild cognitive impairment: A 5-year follow-up study.
    Yoon JH; Kim M; Moon SY; Yong SW; Hong JM
    J Neurol Sci; 2015 Aug; 355(1-2):174-9. PubMed ID: 26076880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating Progression Rates Across the Spectrum of Alzheimer's Disease for Amyloid-Positive Individuals Using National Alzheimer's Coordinating Center Data.
    Potashman M; Buessing M; Levitchi Benea M; Cummings J; Borson S; Pemberton-Ross P; Epstein AJ
    Neurol Ther; 2021 Dec; 10(2):941-953. PubMed ID: 34431074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic validity of the Alzheimer's disease functional assessment and change scale in mild cognitive impairment and mild to moderate Alzheimer's disease.
    Manero RM; Casals-Coll M; Sánchez-Benavides G; Rodríguez-de los Reyes ON; Aguilar M; Badenes D; Molinuevo JL; Robles A; Barquero MS; Antúnez C; Martínez-Parra C; Frank-García A; Fernández M; Blesa R; Peña-Casanova J;
    Dement Geriatr Cogn Disord; 2014; 37(5-6):366-75. PubMed ID: 24556708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
    Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
    Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of performance in neuropsychological tests in amnestic Mild Cognitive Impairment and Alzheimer's disease patients.
    do Vale PHF; Spíndola L; de Oliveira MO; Armentano CGDC; Porto CS; Brucki SMD
    Dement Neuropsychol; 2009; 3(1):41-48. PubMed ID: 29213609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Regression analysis of cerebral blood perfusion and cognitive function in patients with mild cognitive impairment and Alzheimer's disease].
    Xu Y; Chen LL; Su Y; Sun SN; Zhang HY
    Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(3):193-197. PubMed ID: 30669762
    [No Abstract]   [Full Text] [Related]  

  • 31. [Correlation of muscle strength with cognitive function and medial temporal lobe atrophy in patients with mild to moderate Alzheimer's disease].
    Liu SW; Li M; Zhu JT; Zhang YC; Wu YH; Liu CF; Hu H
    Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(35):2786-2792. PubMed ID: 36124351
    [No Abstract]   [Full Text] [Related]  

  • 32. Disrupted Balance of Gray Matter Volume and Directed Functional Connectivity in Mild Cognitive Impairment and Alzheimer's Disease.
    Xiong Y; Ye C; Sun R; Chen Y; Zhong X; Zhang J; Zhong Z; Chen H; Huang M
    Curr Alzheimer Res; 2023; 20(3):161-174. PubMed ID: 37278043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease.
    Silva D; Cardoso S; Guerreiro M; Maroco J; Mendes T; Alves L; Nogueira J; Baldeiras I; Santana I; de Mendonça A
    J Alzheimers Dis; 2020; 74(3):785-796. PubMed ID: 32083585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Souvenaid for Alzheimer's disease.
    Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early detection of cognitive decline in mild cognitive impairment and Alzheimer's disease with a novel eye tracking test.
    Tadokoro K; Yamashita T; Fukui Y; Nomura E; Ohta Y; Ueno S; Nishina S; Tsunoda K; Wakutani Y; Takao Y; Miyoshi T; Higashi Y; Osakada Y; Sasaki R; Matsumoto N; Kawahara Y; Omote Y; Takemoto M; Hishikawa N; Morihara R; Abe K
    J Neurol Sci; 2021 Aug; 427():117529. PubMed ID: 34130064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploratory Longitudinal Study of Ocular Structural and Visual Functional Changes in Subjects at High Genetic Risk of Developing Alzheimer's Disease.
    López-Cuenca I; Sánchez-Puebla L; Salobrar-García E; Álvarez-Gutierrez M; Elvira-Hurtado L; Barabash A; Ramírez-Toraño F; Fernández-Albarral JA; Matamoros JA; Nebreda A; García-Colomo A; Ramírez AI; Salazar JJ; Gil P; Maestú F; Ramírez JM; de Hoz R
    Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of the European Cross-Cultural Neuropsychological Test Battery (CNTB) for the assessment of mild cognitive impairment due to Alzheimer's disease and Parkinson's disease.
    Delgado-Álvarez A; Nielsen TR; Delgado-Alonso C; Valles-Salgado M; López-Carbonero JI; García-Ramos R; Gil-Moreno MJ; Díez-Cirarda M; Matías-Guiu J; Matias-Guiu JA
    Front Aging Neurosci; 2023; 15():1134111. PubMed ID: 37213535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severity Distribution of Alzheimer's Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study.
    Yuan J; Maserejian N; Liu Y; Devine S; Gillis C; Massaro J; Au R
    J Alzheimers Dis; 2021; 79(2):807-817. PubMed ID: 33361590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease.
    Maruff P; Lim YY; Darby D; Ellis KA; Pietrzak RH; Snyder PJ; Bush AI; Szoeke C; Schembri A; Ames D; Masters CL;
    BMC Psychol; 2013; 1(1):30. PubMed ID: 25566378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.